ArGEN-X, a clinical stage human therapeutic antibody company based in Belgium, has appointed Werner Lanthaler to its Supervisory Board.
Lanthaler is currently Chief Executive of Evotec, a role he took in March 2009. Under his leadership Evotec has become a leading drug discovery research organisation.
Before that, he spent nine years as Chief Financial Officer at Intercell (2000-2009). During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine and antibody player.
From 1998 to 2000, Lanthaler was Director of the Federation of Austrian Industry, and from 1995 to 1998 he was a Senior Management Consultant at McKinsey & Company.
